BioCryst Pharmaceuticals, Inc. (BCRX)
BCRX moved a median of -0.08% 30 minutes after news, and -0.45% by the close. How BCRX actually reacts to news — the realized, point-in-time move the market made, measured across 379 labeled events over the last three years with zero look-ahead.
BCRX’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 50% | 378 |
| 30-min | -0.08% | 47% | 379 |
| 60-min | -0.30% | 43% | 379 |
| to close | -0.45% | 43% | 376 |
| Middle 50% of BCRX reactions | -1.09% to +1.06% |
|---|---|
| Median reaction (30-min) | -0.08% |
| Measured reactions | 379 |
Half of all BioCryst Pharmaceuticals, Inc. news events land between -1.09% and +1.06% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How BCRX reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Coverage initiations | 10 | +0.41% | 80% | +0.12% |
| Rating reiterations | 81 | -0.27% | 41% | -0.39% |
| Price-target raises | 18 | -0.23% | 44% | +1.84% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 3 further classes were observed with fewer than 10 measured events and are not published. See how BCRX ranks against every other measured name →
That’s how BCRX usually reacts — get an email when it moves on news →Email me when BCRX moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to BCRX's baseline. Nothing else.
Recent BCRX events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| BioCryst Announces Formation of Scientific Advisory Board to Drive Rare Disease Pipeline Innovation and Growth | Press release | GlobeNewswire | -0.86% | -0.86% | |
| BioCryst to Present at Upcoming Investor Conference | Press release | GlobeNewswire | +0.41% | +2.06% | |
| BioCryst Announces Approval of ORLADEYO® for Pediatric HAE Patients in Japan | Press release | GlobeNewswire | +0.46% | +0.41% | |
| BioCryst Reports Second Quarter 2026 Financial Results | Press release | GlobeNewswire | +1.22% | -3.92% | |
| Form 10-Q BIOCRYST PHARMACEUTICALS For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | +2.88% | |
| Form 8-K BIOCRYST PHARMACEUTICALS For: Aug 05 | SEC filing · Form 8-K | SEC EDGAR | +1.22% | -3.92% | |
| Form S-8 BIOCRYST PHARMACEUTICALS | SEC filing · Form S-8 | SEC EDGAR | +0.00% | +2.88% | |
| Form 8-K/A BIOCRYST PHARMACEUTICALS For: Jun 25 | SEC filing · Form 8-K | SEC EDGAR | +0.45% | +2.27% | |
| BioCryst to Report Second Quarter 2026 Financial Results on August 5 | Press release | GlobeNewswire | +1.17% | +1.49% | |
| BioCryst Appoints David W. Jenkins as Chief Scientific Officer | Press release | GlobeNewswire | -1.84% | -3.88% | |
| BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -1.33% | +1.03% | |
| BioCryst Sharpens Scientific Focus on External Innovation with Wind Down of Internal Discovery Programs and Closure of Birmingham Research Facility | Press release | GlobeNewswire | +0.35% | -3.44% | |
| Form 8-K BIOCRYST PHARMACEUTICALS For: Jun 25 | SEC filing · Form 8-K | SEC EDGAR | +0.35% | -3.44% | |
| BioCryst Presents New Clinical Data and Real-World Evidence Demonstrating Impact of HAE Portfolio at the 2026 European Academy of Allergy and Clinical Immunology Annual Meeting | Press release | GlobeNewswire | +0.83% | +2.71% | |
| Form 8-K BIOCRYST PHARMACEUTICALS For: Jun 11 | SEC filing · Form 8-K | SEC EDGAR | +0.80% | +3.42% | |
| BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -0.66% | -1.44% | |
| BioCryst to Present New HAE Data from ORLADEYO® (berotralstat) and Navenibart at the 2026 European Academy of Allergy and Clinical Immunology Annual Meeting | Press release | GlobeNewswire | +0.59% | +7.55% | |
| BioCryst to Present New Real-World Evidence Underscoring the Ongoing Burden of Pediatric Hereditary Angioedema at ISPOR 2026 | Press release | GlobeNewswire | +1.15% | +10.60% | |
| BioCryst Reports First Quarter 2026 Financial Results and Provides Business Update | Press release | GlobeNewswire | -6.72% | +3.88% | |
| Form 10-Q BIOCRYST PHARMACEUTICALS For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -1.36% | +1.14% | |
| Form 8-K BIOCRYST PHARMACEUTICALS For: May 06 | SEC filing · Form 8-K | SEC EDGAR | -6.72% | +3.88% | |
| BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -0.03% | -2.06% | |
| BioCryst Announces European Licensing Agreement with Irish Affiliate of Neopharmed Gentili for Navenibart in Hereditary Angioedema | Press release | GlobeNewswire | +0.76% | +0.44% | |
| Form 8-K BIOCRYST PHARMACEUTICALS For: May 04 | SEC filing · Form 8-K | SEC EDGAR | +0.76% | +0.44% | |
| BioCryst to Present at Upcoming Investor Conferences | Press release | GlobeNewswire | +0.39% | -1.99% | |
| Form ARS BIOCRYST PHARMACEUTICALS For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -0.23% | +2.52% | |
| Form DEF 14A BIOCRYST PHARMACEUTICALS For: Jun 11 | SEC filing · Form DEF | SEC EDGAR | -0.23% | +2.52% | |
| Form DEFA14A BIOCRYST PHARMACEUTICALS | SEC filing · Form DEFA14A | SEC EDGAR | -0.23% | +2.52% | |
| BioCryst to Report First Quarter 2026 Financial Results on May 6 | Press release | GlobeNewswire | -1.69% | -3.18% | |
| BioCryst Appoints Sandeep M. Menon Chief Research and Development Officer | Press release | GlobeNewswire | +1.34% | +5.46% | |
| BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +1.34% | +5.46% | |
| BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -0.35% | -1.04% | |
| BioCryst Reports Full Year 2025 Financial Results and Provides Business Update | Press release | GlobeNewswire | -4.91% | -3.07% | |
| Form 10-K BIOCRYST PHARMACEUTICALS For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +4.78% | +10.06% | |
| Form 8-K BIOCRYST PHARMACEUTICALS For: Feb 26 | SEC filing · Form 8-K | SEC EDGAR | -4.91% | -3.07% | |
| BioCryst to Present at Upcoming Investor Conference | Press release | GlobeNewswire | +1.18% | +2.51% | |
| BioCryst to Present New HAE Data from ORLADEYO® (berotralstat) and Navenibart at the 2026 American Academy of Allergy, Asthma & Immunology Annual Meeting | Press release | GlobeNewswire | -0.38% | +4.75% | |
| BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +0.78% | -3.11% | |
| BioCryst to Report Fourth Quarter 2025 Financial Results on February 26 | Press release | GlobeNewswire | +0.78% | -3.11% | |
| BioCryst Completes Acquisition of Astria Therapeutics, Expanding Leadership in Hereditary Angioedema | Press release | GlobeNewswire | +2.98% | +1.04% | |
| Form 8-K BIOCRYST PHARMACEUTICALS For: Jan 23 | SEC filing · Form 8-K | SEC EDGAR | +1.92% | +1.03% | |
| Form 8-K/A BIOCRYST PHARMACEUTICALS For: Oct 14 | SEC filing · Form 8-K | SEC EDGAR | +1.92% | +1.03% | |
| BioCryst Announces Preliminary Full Year 2025 ORLADEYO® (berotralstat) Net Revenue of $601 Million (+37 percent y-o-y), Beating Prior Guidance Range | Press release | GlobeNewswire | -3.42% | -2.88% | |
| Form 8-K BIOCRYST PHARMACEUTICALS For: Jan 12 | SEC filing · Form 8-K | SEC EDGAR | -4.28% | -5.33% | |
| Form 8-K BIOCRYST PHARMACEUTICALS For: Jan 09 | SEC filing · Form 8-K | SEC EDGAR | +1.56% | -3.27% | |
| BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +1.02% | +2.85% | |
| BioCryst to Present at 44th Annual J.P. Morgan Healthcare Conference | Press release | GlobeNewswire | +1.02% | +2.85% | |
| Form EFFECT BIOCRYST PHARMACEUTICALS | SEC filing · Form EFFECT | SEC EDGAR | +0.84% | +2.35% | |
| Form S-4/A BIOCRYST PHARMACEUTICALS | SEC filing · Form S-4 | SEC EDGAR | +2.94% | -0.78% | |
| BioCryst Announces FDA Approval of ORLADEYO® (berotralstat) Oral Pellets, First and Only Oral Prophylactic Treatment for Patients with HAE Aged 2 to <12 Years | Press release | GlobeNewswire | -3.21% | -3.20% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the BCRX section they belong to.
Where else BCRX is measured.
BCRX earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| CORIUM INTL (CORI) | 380 | 0.00% | 46% |
| PROTEON THERAPEUTICS (PRTO) | 380 | 0.00% | 39% |
| Constellation Pharmaceuticals, Inc (CNST) | 379 | 0.00% | 44% |
| CONTRAVIR PHARMACEUTICALS INC (CTRV) | 379 | -0.51% | 36% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is BioCryst Pharmaceuticals, Inc.'s median reaction calculated?
Every labeled BCRX news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 379 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 47% of BCRX's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does BCRX's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.